# 2025年12月26日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 磁共振成像阴性小儿癫痫的神经结构发育异常：一项涵盖1919名儿童的大规模多中心研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444855)
**期刊：** Epilepsia
**PMID：** 41444855
**DOI：** 10.1002/epi.70065

### 第一部分 原文与翻译

**英文原标题：** Altered neurostructural development in magnetic resonance imaging-negative pediatric epilepsy: A large-scale multicenter study of 1919 children.

> **英文摘要：**
> OBJECTIVE: Addressing the poorly understood impact of pediatric epilepsy on neurodevelopment, this large-scale study delineates age- and sex-stratified neurostructural trajectories in magnetic resonance imaging (MRI)-negative pediatric epilepsy to identify periods of maximal developmental divergence from healthy controls.
> 
> METHODS: In this multicenter, cross-sectional study, we analyzed T1-weighted MRI from 957 patients with MRI-negative epilepsy and 962 controls (aged 4-12 years). Generalized additive models for location, scale, and shape modeled sex-stratified developmental trajectories of global brain metrics. Voxel- and surface-based morphometry compared cortical morphology and regional gray matter volume (GMV) between groups across yearly age bins (familywise error-corrected p < .05).
> 
> RESULTS: Compared to controls, patients showed reduced total intracranial volume, GMV, cerebrospinal fluid volume, and cortical thickness and significantly increased white matter hyperintensity burden. Key findings on developmental trajectories include an atypical trajectory of total surface area, a premature cortical thickness peak at approximately age 7 years, and a white matter hyperintensity (WMH) burden peak at approximately age 8 years. From ages 4 to 9 years, patients displayed widespread cortical morphological delays, most prominently affecting limbic and sensorimotor networks, which appeared to normalize after age 10 years. Unlike the GMV atrophy seen in adults, pediatric patients showed limbic expansion (5-6 years), thalamic hypertrophy (9-12 years), and cerebellar volumetric shifts.
> 
> SIGNIFICANCE: Our findings indicate that pediatric epilepsy is a disorder of aberrant neurodevelopment with two distinct signatures. First, we identify a critical 4-9-year vulnerability window characterized by profound but transient deviations, including atypical cortical maturation, increased WMH burden, and widespread morphological delays. These delays appeared to normalize after age 10 years, a finding that requires longitudinal validation. Second, we uncover a progressive, potentially persistent alteration: a hierarchical expansion of gray matter initiating in the limbic system and later involving the thalamus. These signatures provide distinct biomarkers to differentiate transient disruption from ongoing network reorganization, offering new targets for timed interventions.

> **中文摘要：**
> 研究目的：为了解小儿癫痫对神经发育影响这一尚缺乏深入认识的问题，本项大规模研究描绘了磁共振成像（MRI）阴性小儿癫痫患者按年龄和性别分层的神经结构发育轨迹，以确定其与健康对照之间发育差异最显著的阶段。
> 
> 研究方法：本研究采用多中心横断面设计，分析了957例MRI阴性癫痫患儿与962名健康对照（年龄4–12岁）的T1加权MRI数据。利用位置–尺度–形状的广义加性模型，对按性别分层的全脑结构发育轨迹进行建模。基于体素和表面的形态学分析（经家族式错误校正，p < 0.05）比较了两组在各年度年龄区间内的皮质形态结构及区域灰质体积（GMV）差异。
> 
> 研究结果：与对照组相比，患者表现出总颅内容积、GMV、脑脊液体积及皮质厚度的降低，以及白质高信号负担显著增加。发育轨迹的主要发现包括：整体表面积发育异常，皮质厚度在约7岁时提前达到峰值，白质高信号（WMH）负担在约8岁时达到峰值。在4至9岁期间，患者表现出广泛的皮质形态发育延迟，最明显见于边缘系统和感觉运动网络，而这些差异似乎在10岁后趋于正常。与成人癫痫中见到的灰质萎缩不同，小儿患者表现出边缘系统扩张（5–6岁）、丘脑肥大（9–12岁）及小脑体积变化。
> 
> 研究意义：结果表明，小儿癫痫是一种神经发育异常性疾病，存在两种不同特征。首先，研究揭示出一个关键的4–9岁易感期，其特点是深刻但暂时性的偏离，包括异常的皮质成熟、增加的WMH负担和广泛的形态发育延迟；这些延迟在10岁后似乎恢复正常，该发现尚需纵向验证。其次，研究发现一种渐进且可能持续的改变：灰质的分层性扩张起始于边缘系统，随后波及丘脑。这些特征为区分短暂性发育中断与持续性网络重组提供了明确的生物标志，并为时机化干预提供了新的靶点。

### 第二部分 AI 大师评价

本研究通过多中心大样本的结构MRI分析，系统刻画了MRI阴性小儿癫痫的脑发育轨迹，揭示了其特有的发育异常阶段。研究发现4–9岁是最显著的发育偏离窗口，表现为皮质成熟异常和白质高信号增加，且这些变化在10岁后趋于恢复。同时发现了灰质在边缘系统到丘脑的渐进性扩张模式，提示其潜在的持续性网络重组。本研究为小儿癫痫的神经发育机制提供了新的生物标志和干预时机，但仍需纵向随访验证其时序关系与因果机制。

---

## 2. 癫痫患儿生酮饮食治疗减停的回顾性研究见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41443991)
**期刊：** Epilepsia
**PMID：** 41443991
**DOI：** 10.1002/epi.70078

### 第一部分 原文与翻译

**英文原标题：** Weaning from ketogenic diet therapy in children with epilepsy: Insights from a retrospective study.

> **英文摘要：**
> OBJECTIVE: This study was undertaken to describe weaning practices following ketogenic diet therapy (KDT) in children with epilepsy and to identify clinical factors associated with seizure exacerbation or antiseizure medication adjustments during or after weaning from KDT.
> 
> METHODS: This retrospective observational study examined patients who initiated and discontinued KDT between 2016 and 2022 at a tertiary epilepsy center. Patients with GLUT1 deficiency, ongoing KDT, or less than 1 year of follow-up postdiscontinuation were excluded. Clinical, electroencephalographic (EEG), magnetic resonance imaging, KDT response, weaning duration, and seizure outcomes were analyzed. Responders were defined by ≥50% seizure reduction. Seizure worsening and/or antiseizure medication (ASM) adjustments during weaning were the primary outcomes.
> 
> RESULTS: Among 57 evaluable patients, 49% were responders and 25% became seizure-free. During weaning, 62% experienced seizure exacerbation or required ASM modifications. Unfavorable outcomes were significantly associated with shorter KDT duration, shorter weaning periods, higher ASM burden, and abnormal preweaning EEG. Among responders, seizure worsening was not significantly linked to weaning speed alone. At 1 year, seizure freedom was more common in patients who did not experience any issue during the weaning (65% vs. 30%, p = .009).
> 
> SIGNIFICANCE: Our findings underscore the importance of individualized KDT discontinuation plans based on efficacy, EEG activity, and ASM burden. Although prolonged weaning was more common in responders, weaning duration alone did not predict outcomes. These results highlight the need for prospective studies to define optimal weaning strategies for KDT.

> **中文摘要：**
> 目的：本研究旨在描述癫痫患儿在生酮饮食治疗（KDT）后的减停实践，并识别在KDT减停期间或之后与癫痫发作加重或抗癫痫药物（ASM）调整相关的临床因素。
> 
> 方法：这项回顾性观察研究纳入了2016年至2022年在一家三级癫痫中心开始并停止KDT的患者。排除了存在GLUT1缺乏症、仍在接受KDT或停用后随访不足1年的患者。分析内容包括临床资料、脑电图（EEG）、磁共振成像（MRI）、KDT疗效、减停持续时间及癫痫发作结局。疗效应答者定义为癫痫发作减少≥50%。减停过程中癫痫发作加重和/或抗癫痫药物调整为主要评价结局。
> 
> 结果：在57名可评估患者中，49%为应答者，25%实现了无发作状态。在减停过程中，62%的患者出现癫痫发作加重或需要调整抗癫痫药物。不良结局显著关联于较短的KDT持续时间、较短的减停期、更高的抗癫痫药物负担以及减停前异常的EEG表现。在应答者中，癫痫发作加重与减停速度本身无显著相关性。1年随访时，减停过程中未出现任何问题的患者更容易达到无发作状态（65% 对 30%，p = .009）。
> 
> 意义：我们的研究结果强调了基于疗效、脑电活动及抗癫痫药物负荷制定个体化KDT停用方案的重要性。尽管延长减停阶段在应答者中更为常见，但减停持续时间本身并不能预测结局。这些结果提示需要前瞻性研究以明确KDT最优减停策略。

### 第二部分 AI 大师评价

该研究以回顾性方法探讨了癫痫患儿停止生酮饮食治疗的临床实践及其风险因素，揭示了减停过程中癫痫发作加重与疗程长度、减停时长、药物负担及EEG异常的相关性。结果表明减停速度并非唯一影响结局的因素，凸显了个体化KDT停止策略的必要性。研究为优化KDT停用方案提供了循证依据，但由于样本量有限及回顾性设计，仍需前瞻性研究进一步验证。

---

## 3. 倡导构建伦理、公平且高效的人工智能以改善所有癫痫患者的照护：路线图——国际抗癫痫联盟全球倡导委员会与大数据委员会报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41443971)
**期刊：** Epilepsia
**PMID：** 41443971
**DOI：** 10.1002/epi.70058

### 第一部分 原文与翻译

**英文原标题：** A call for ethical, equitable, and effective artificial intelligence to improve care for all people with epilepsy: A roadmap. A report by the ILAE Global Advocacy Council and Big Data Commission.

> **英文摘要：**
> The artificial intelligence (AI) revolution is upon us. It will inevitably form a central component of epilepsy workflows and patient advocacy. Therefore, it behooves us as health care providers to ride the crest of this wave and guide its direction for the benefit of all people with epilepsy. Emerging AI-based solutions include decision support tools, automated interpretation of electroencephalography (EEG) and brain imaging, and wearable devices that detect seizures and improve patient safety. Pipelines, including decentralized approaches and federated learning, are now being built that will democratize access and facilitate the next generation of AI tools for the global epilepsy community. Despite this, enduring issues remain incompletely addressed. For example, AI requires high volumes of data, leading to concerns about ethical ownership, stewardship, and privacy. Few AI-based tools have progressed from derivation to validation stages, and only rare exceptions undergo real-world evaluation. Inadvertent harmful algorithmic and decision allocation biases also continue to represent major risks to the global epilepsy population. Additional barriers include geographical disparities in computing resources, proprietary ownership of electronic health records, EEG, and brain-imaging platforms, and greenhouse gas emissions related to the demanding power requirements of AI. Therefore, to fully avail ourselves of the benefits of AI, we assert that ethical, equitable, and effective AI for epilepsy requires collaboration from the entirety of the global epilepsy community. Fundamental to this is early and deliberate engagement of people from low- and middle-income countries to ensure that AI-based solutions do not exacerbate existing global disparities. Ultimately, we advocate for "decision intelligence" approaches to the development of AI-based epilepsy solutions, which involves early engagement of all interest-holders to ensure that the correct questions are addressed and the right technical approaches are deployed to maximize value for the global epilepsy community.

> **中文摘要：**
> 人工智能（AI）革命正在到来。它将不可避免地成为癫痫工作流程和患者倡导的核心组成部分。因此，作为医疗服务提供者，我们应当顺势而为，引导其方向，以惠及所有癫痫患者。新兴的基于AI的解决方案包括决策支持工具、脑电图（EEG）和脑成像的自动化解读，以及能够检测发作并提升患者安全性的可穿戴设备。目前正在构建的流程——包括去中心化方式和联邦学习——将实现访问民主化，并促进全球癫痫社区新一代人工智能工具的发展。尽管如此，仍存在未充分解决的长期问题。例如，AI需要大量数据，导致对伦理所有权、管理责任和隐私的担忧。极少有AI工具从建立阶段发展到验证阶段，只有个别例外经历了现实环境的评估。无意中产生的有害算法及决策分配偏差仍是全球癫痫群体面临的重大风险。其他障碍还包括计算资源的地理差异、电子病历、EEG及脑影像平台的专有权，以及AI高能耗带来的温室气体排放。因此，为充分利用AI带来的益处，我们认为构建伦理、公平且高效的癫痫人工智能，需要全球癫痫社区的全面协作。尤其重要的是，应在早期有意地吸纳中低收入国家的参与者，以确保AI相关解决方案不加剧现有的全球差异。最终，我们倡导将“决策智能”理念应用于AI癫痫解决方案的开发过程中，即在早期广泛吸纳所有利益相关方，确保提出正确的问题、采取恰当的技术路径，从而最大化AI对全球癫痫社区的价值。

### 第二部分 AI 大师评价

本文旨在呼吁全球癫痫领域在AI发展浪潮下共同构建具备伦理、公平与高效性的人工智能框架。文章系统分析了AI在癫痫诊疗中潜在的应用场景，如决策支持与脑电图自动化分析，同时指出现实中的数据依赖、算法偏倚及资源不均等挑战。其创新之处在于提出“决策智能”的概念，强调自早期即广泛吸纳多方利益相关者参与，尤其重视中低收入国家的声音。然而，该报告主要为理念性和倡议性文件，缺乏具体量化方法与实施细节，需后续研究进一步落地。

---

速递结束，祝您工作愉快！